Short answer
CVRx, Inc. (CVRX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
CVRx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1, including performance metrics and outlook
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $13.8M, down 6%; U.S. revenue $13.0M, down 4%, reflecting lower sales-force productivity and payer pressure
- Active U.S. implanting centers rose to 262 from 250, while sales territories increased to 56 from 50
- FY2026 revenue guidance cut to $56.0M-$57.0M from $58.0M-$60.0M, signaling weaker near-term commercial execution
- Net loss widened to $14.2M, or $0.52 per share, with cash $58.7M and debt $58.7M at September 30
- Medicare Advantage coverage expanded to policies representing approximately 21% of enrollment, supporting longer-term Barostim adoption potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CVRx, Inc. 8-K filings
Get the next CVRX 8-K as it lands
Follow CVRX for push alerts, or ask the research agent what this filing means.